Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best penny stocks to buy for 2026. On January 6, the company confirmed that the dosing of the first patient in the REVELA pivotal trial began. The trial is evaluating TSHA-102, a gene therapy for Rett syndrome.

The trial is poised to evaluate 15  females between the ages of 6 and 22 years with Rett syndrome. The focus is on ascertaining the response rate, which is the percentage of patients who gain or regain one or more of 28 natural history-defined developmental milestones.  The company will complete dosing in both the REVEAL pivotal trial and ASPIRE trial in the second quarter.

The Rett syndrome trial comes in Jefferies, reiterating Taysha Gene Therapies as a promising biotech company poised for significant growth in 2026. The research firm expects the stock to receive a boost from pivotal trial data and regulatory milestones across multiple therapeutic areas. The firm has touted the company’s Rett syndrome therapy, TSHA-102, owing to its potential to generate $2 billion in peak revenue.

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is a clinical-stage biotech company developing adeno-associated virus (AAV)-based gene therapies to cure severe, single-gene (monogenic) disorders of the central nervous system, with a primary focus on Rett syndrome and the aim of providing disease-modifying treatments for debilitating neurological conditions.

While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.